Correction to: Safety and Effectiveness of Ipragliflozin for Type 2 Diabetes in Japan: 12-Month Interim Results of the STELLA-LONG TERM Post-Marketing Surveillance Study (Advances in Therapy, (2019), 36, 4, (923-949), 10.1007/s12325-019-0895-1)

Ichiro Nakamura; Hiroshi Maegawa; Kazuyuki Tobe; Satoshi Uno

doi:10.1007/s12325-021-01813-8

Correction to: Safety and Effectiveness of Ipragliflozin for Type 2 Diabetes in Japan: 12-Month Interim Results of the STELLA-LONG TERM Post-Marketing Surveillance Study (Advances in Therapy, (2019), 36, 4, (923-949), 10.1007/s12325-019-0895-1)

Ichiro Nakamura^*, Hiroshi Maegawa, Kazuyuki Tobe, Satoshi Uno

^*Corresponding author for this work

Internal Medicine （1）

Research output: Contribution to journal › Comment/debate

Abstract

In the original article, the Table 6 was published with some errors. The correct Table 6 is below. (Table presented.).

Original language	English
Pages (from-to)	4599-4601
Number of pages	3
Journal	Advances in Therapy
Volume	38
Issue number	8
DOIs	https://doi.org/10.1007/s12325-021-01813-8
State	Published - 2021/08

ASJC Scopus subject areas

Pharmacology (medical)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s12325-021-01813-8

Fingerprint

Dive into the research topics of 'Correction to: Safety and Effectiveness of Ipragliflozin for Type 2 Diabetes in Japan: 12-Month Interim Results of the STELLA-LONG TERM Post-Marketing Surveillance Study (Advances in Therapy, (2019), 36, 4, (923-949), 10.1007/s12325-019-0895-1)'. Together they form a unique fingerprint.

Cite this

Nakamura, I., Maegawa, H., Tobe, K., & Uno, S. (2021). Correction to: Safety and Effectiveness of Ipragliflozin for Type 2 Diabetes in Japan: 12-Month Interim Results of the STELLA-LONG TERM Post-Marketing Surveillance Study (Advances in Therapy, (2019), 36, 4, (923-949), 10.1007/s12325-019-0895-1). Advances in Therapy, 38(8), 4599-4601. https://doi.org/10.1007/s12325-021-01813-8

Nakamura, Ichiro ; Maegawa, Hiroshi ; Tobe, Kazuyuki et al. / Correction to : Safety and Effectiveness of Ipragliflozin for Type 2 Diabetes in Japan: 12-Month Interim Results of the STELLA-LONG TERM Post-Marketing Surveillance Study (Advances in Therapy, (2019), 36, 4, (923-949), 10.1007/s12325-019-0895-1). In: Advances in Therapy. 2021 ; Vol. 38, No. 8. pp. 4599-4601.

@article{5e4dbceea598410e9535ab9bb2e49f2d,

title = "Correction to: Safety and Effectiveness of Ipragliflozin for Type 2 Diabetes in Japan: 12-Month Interim Results of the STELLA-LONG TERM Post-Marketing Surveillance Study (Advances in Therapy, (2019), 36, 4, (923-949), 10.1007/s12325-019-0895-1)",

abstract = "In the original article, the Table 6 was published with some errors. The correct Table 6 is below. (Table presented.).",

author = "Ichiro Nakamura and Hiroshi Maegawa and Kazuyuki Tobe and Satoshi Uno",

note = "Publisher Copyright: {\textcopyright} Springer Healthcare Ltd., part of Springer Nature 2021",

year = "2021",

month = aug,

doi = "10.1007/s12325-021-01813-8",

language = "英語",

volume = "38",

pages = "4599--4601",

journal = "Advances in Therapy",

issn = "0741-238X",

publisher = "Adis",

number = "8",

}

Nakamura, I, Maegawa, H, Tobe, K & Uno, S 2021, 'Correction to: Safety and Effectiveness of Ipragliflozin for Type 2 Diabetes in Japan: 12-Month Interim Results of the STELLA-LONG TERM Post-Marketing Surveillance Study (Advances in Therapy, (2019), 36, 4, (923-949), 10.1007/s12325-019-0895-1)', Advances in Therapy, vol. 38, no. 8, pp. 4599-4601. https://doi.org/10.1007/s12325-021-01813-8

Correction to: Safety and Effectiveness of Ipragliflozin for Type 2 Diabetes in Japan: 12-Month Interim Results of the STELLA-LONG TERM Post-Marketing Surveillance Study (Advances in Therapy, (2019), 36, 4, (923-949), 10.1007/s12325-019-0895-1). / Nakamura, Ichiro; Maegawa, Hiroshi; Tobe, Kazuyuki et al.
In: Advances in Therapy, Vol. 38, No. 8, 08.2021, p. 4599-4601.

Research output: Contribution to journal › Comment/debate

TY - JOUR

T1 - Correction to

T2 - Safety and Effectiveness of Ipragliflozin for Type 2 Diabetes in Japan: 12-Month Interim Results of the STELLA-LONG TERM Post-Marketing Surveillance Study (Advances in Therapy, (2019), 36, 4, (923-949), 10.1007/s12325-019-0895-1)

AU - Nakamura, Ichiro

AU - Maegawa, Hiroshi

AU - Tobe, Kazuyuki

AU - Uno, Satoshi

PY - 2021/8

Y1 - 2021/8

N2 - In the original article, the Table 6 was published with some errors. The correct Table 6 is below. (Table presented.).

AB - In the original article, the Table 6 was published with some errors. The correct Table 6 is below. (Table presented.).

UR - http://www.scopus.com/inward/record.url?scp=85110803486&partnerID=8YFLogxK

U2 - 10.1007/s12325-021-01813-8

DO - 10.1007/s12325-021-01813-8

M3 - コメント/討論

C2 - 34279807

AN - SCOPUS:85110803486

SN - 0741-238X

VL - 38

SP - 4599

EP - 4601

JO - Advances in Therapy

JF - Advances in Therapy

IS - 8

ER -